Farmas USA

SNSS:

Miercoles 12 Agosto Daniel Swisher, director General de SNSS presentará en el 2015 Wedbush Pac Grow una conferencia.

Snss

XOMA

Mañana tiene call.

Joer, mañana ya es jueves, qué rápido pasa la semana bursátil. :-(

XOMA:

Sí, el jueves, después del cierre de mercados, se anunciarán los resultados del trimestre...!!!

Vaya, premarket jugueton, 1k cromos a 12.10

NVAX

edito: otros 1k y vuelta a 11.76 ... 

ADXS

2 becas de 1 millón cada una del Movember Foundation-PCF Challenge Awards awarded to two ADXS-PSA teams conducting innovative large-scale research projects concerning metastatic, treatment-resistant prostate cancer, an advanced form of the disease with often-lethal outcomes.

http://www.streetinsider.com/Corporate+News/Advaxis+%28ADXS%29+Awarded+Two+Research+Grants+for+ADXS-PSA+Development/10782836.html?si_client=intbro

OCAT

FN Media Group LLC

"Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions"

Cooperative research and development agreements between biotech companies, military surgical research and top-tier universities for identifying biotech solutions & therapies with regards to severe wound treatments for critical-care patients lead to positive clinical enhancements for regenerative medicine and tissue-engineered skin substitute advancements. Biotech companies with recent developments, partnerships and advancements in focus are Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), Osiris Therapeutics, Inc. (NASDAQ: OSIR), Ocata Therapeutics, Inc. (NASDAQ: OCAT), Oragenics, Inc. (NYSE: OGEN) and ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)

Ocata Therapeutics, Inc. (NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced this month that it continues to fortify the patent protection covering its retinal pigment epithelium (RPE) transplant technology for macular degeneration with the issuance by the United States Patent and Trademark Office (USPTO) of U.S. Patent No 9,080,150. "The issuance of this 9th U.S. patent in our global RPE portfolio represents yet another example of the leadership position we have established as pioneers in Regenerative Ophthalmology," said Paul K. Wotton, Ph.D., President and Chief Executive Officer. "In particular, this new patent provides coverage for the manufacture of all RPE products from any pluripotent source by defining the basic universal markers of RPE essential for therapeutic use. We have recently received patent protection for the manufacture of human RPE cell products from pluripotent stem cell sources, including manufacture of formulation forms for use as therapeutic agents as well as the use of these RPE formulations for treating degenerative ophthalmic diseases, such as dry age-related macular degeneration (dry AMD) and Stargardt's macular degeneration (SMD)."

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20150803:B:1

OCAT

Blackrock ha disminuido en el último movimiento (-11,557) pero ya pasa del millón (no había mirado en los últimos días): 1,043,417

12,75% de institucionles + 1,12 de insiders.

esos institucionales van creciendo, eh?????? :))))))

OCAT